Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8395 USD | +7.13% | +4.94% | -42.50% |
Business Summary
Number of employees: 11
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
ViraxClear and ViraxImmune
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, Hong Kong, Singapore, China, British Virgin Islands
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
Jason Davis
DFI | Director of Finance/CFO | 52 | 22-05-01 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Tomasz George
CTO | Chief Tech/Sci/R&D Officer | 40 | 21-01-31 |
Nigel McCracken
COO | Chief Operating Officer | - | 23-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nelson Haight
BRD | Director/Board Member | 59 | - |
Evan Norton
BRD | Director/Board Member | 49 | - |
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Yair Erez
BRD | Director/Board Member | 50 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,361,903 | 1,729,013 ( 73.20 %) | 0 | 73.20 % |
Company contact information
Sector
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.50% | 1.85M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- VRAX Stock
- Company Virax Biolabs Group Limited